Zynrelef Solution
Product Images NDC 47426-503

Product Visual Gallery

This gallery contains 50 technical images submitted to the FDA as part of the official labeling for Zynrelef (NDC 47426-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Heron Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Zynrelef 01)

An illustration showing a close-up cross-section of skin with a needle or syringe inserted into it, depicting the injection process. The image emphasizes the penetration of the needle through the skin layers, related to the administration of a pharmaceutical product such as ZYNRELEF.*

FDA Label Image

Chemical Structure (Zynrelef 02)

Chemical structure of the active ingredient in ZYNRELEF, showing a molecular diagram with a nitrogen-containing cyclic group, aromatic ring with two methyl substituents, and other functional groups. The image depicts bonds and atoms typical of the compound's chemical formulation.*

FDA Label Image

Chemical Structure (Zynrelef 03)

Chemical structure diagram of the active ingredient featured in ZYNRELEF. The diagram shows the molecular arrangement including rings, hydroxyl, carbonyl, sulfonyl, methyl, and thiazole groups as part of the compound's structure.*

FDA Label Image

Figure 1 (Zynrelef 04)

A line graph depicting NRS-A Pain Intensity Score (Mean ± SE) over hours post study drug administration. It compares pain scores for ZYNRELEF 60 mg/1.8 mg, Bupivacaine HCl 50 mg, and a Saline Placebo across time points from 1 to 72 hours.*

FDA Label Image

Figure 2 (Zynrelef 05)

A line graph showing the mean NRS-A pain intensity scores with standard error over 72 hours post study drug administration for three groups: ZYNRELEF 300 mg/9 mg, Bupivacaine HCl 75 mg, and Saline Placebo. The x-axis represents hours post administration, and the y-axis shows pain intensity scores. ZYNRELEF scores remain lower compared to the other two groups throughout the 72-hour period.*

FDA Label Image

Figure 3 (Zynrelef 06)

A line graph depicting NRS-R Pain Intensity Scores over 72 hours post study drug administration for three groups: ZYNRELEF 400 mg/12 mg (N=58), ZYNRELEF 400 mg/12 mg plus Ropivacaine 50 mg (N=56), and Saline Placebo (N=53). The x-axis represents hours post administration, and the y-axis shows pain scores with mean ± SE. The graph compares pain intensity changes over time across the groups.*

FDA Label Image

Image (Zynrelef 83)

Carton label for ZYNRELEF extended-release solution containing 400 mg bupivacaine and 12 mg meloxicam per 14 mL vial. The label states it is for single-dose application for soft tissue or periarticular instillation use. Manufacturer is Heron Therapeutics, Inc. Instructions note vial contents are sterile, with specific storage and usage details.*

FDA Label Image

Image (Zynrelef 84)

ZYNRELEF 300 mg bupivacaine and 9 mg meloxicam extended-release solution single-dose application carton, labeled for soft tissue or periarticular instillation use. The packaging indicates it contains a vial with 10.5 mL sterile contents and components for administration, including syringes and applicators. Manufactured by Heron Therapeutics, Inc.*

FDA Label Image

Image (Zynrelef 85)

ZYNRELEF packaging label for the 200 mg bupivacaine and 6 mg meloxicam extended-release solution. The label specifies a single-dose application for soft tissue or periarticular instillation use with vial contents of 7 mL. It is manufactured by Heron Therapeutics, Inc. and includes instructions to refer to prescribing information and usage directions. The label also highlights storage conditions and sterile vial contents.*

FDA Label Image

Image (Zynrelef 86)

ZYNRELEF packaging label for a 60 mg bupivacaine and 1.8 mg meloxicam extended-release solution. The label indicates a single-dose vial with 2.3 mL contents, intended for soft tissue or periarticular instillation use. It includes storage and handling instructions and identifies Heron Therapeutics, Inc. as the manufacturer.*

FDA Label Image

Image (Zynrelef 87)

An instructional illustration showing a hand pressing down on the top of a cylindrical device with a purple base, accompanied by a downward arrow indicating the direction of pressing or activation.*

FDA Label Image

Image (Zynrelef 88)

ZYNRELEF 200 mg/7mL and 400 mg/14mL subcutaneous injection carton from Heron Therapeutics, Inc. The front of the package displays the proprietary name ZYNRELEF along with the concentrations 200 mg/7mL and 400 mg/14mL. The label includes dosage form and volume details, with the Heron Therapeutics logo at the bottom.*

FDA Label Image

Image (Zynrelef 89)

ZYNRELEF 200 with strengths of 6 mg/7 mL and 400 with 12 mg/14 mL. The packaging label shows the product name prominently, indicating active ingredient strengths and volume, along with the labeler Heron Therapeutics, Inc. The image displays a white container with green and black text on a yellow background.*

FDA Label Image

Image (Zynrelef 90)

An instructional illustration showing hands snapping off the top of a ZYNRELEF vial, demonstrating how to open the vial prior to use.*

FDA Label Image

Image (Zynrelef 91)

The carton shown is for ZYNRELEF, featuring two available strengths: 6 mg/7 mL and 12 mg/14 mL. It is a pharmaceutical product by Heron Therapeutics, Inc., with the brand name and strength prominently displayed on the front panel along with usage and identification markings.*

FDA Label Image

Image (Zynrelef 92)

An instructional illustration showing a hand twisting the plunger of a syringe attached to a vial, demonstrating the process of preparing a medication dose. The vial and syringe are depicted clearly with arrows indicating the twisting motion needed to operate the device.*

FDA Label Image

Image (Zynrelef 93)

An instructional illustration showing how to attach a syringe to a medication vial or device. The image highlights the 'Drug inlet' on the container with a magnified view and depicts a hand holding a syringe with volume markings from 0 to 12 mL, positioned for drawing medication.*

FDA Label Image

Image (Zynrelef 94)

An instructional illustration showing a hand holding a syringe with a vial adapter attached. The image depicts the process of drawing medication from a vial into the syringe, highlighting the syringe's measurement markings.*

FDA Label Image

Image (Zynrelef 95)

Illustration showing the proper method of attaching a syringe to a vial, with a hand holding the vial and another hand connecting the syringe to the vial's top. An inset shows a detailed close-up of the syringe with measurement markings, likely related to dosing for ZYNRELEF by Heron Therapeutics, Inc.*

FDA Label Image

Image (Zynrelef 96)

FDA Label Image

Image (Zynrelef 97)

An instructional illustration showing a syringe injecting medication into a cross-section of skin with a cut or wound. The image demonstrates the method of delivering an injectable drug into the affected area beneath the skin surface.*

FDA Label Image

Image (Zynrelef 98)

FDA Label Image

Image (Zynrelef 99)

FDA Label Image

Image (Zynrelef 100)

FDA Label Image

Image (Zynrelef 119)

Illustration showing components of ZYNRELEF administration set, including a vial with a blue cap, a syringe with measurement markings, a nozzle or adapter, a small blue cap or stopper, and a bottle. An advisory note states not to substitute any components. Instructions prompt to turn over for administration information.*

FDA Label Image

Image (Zynrelef 120)

An instructional illustration showing medical components including a syringe with volume markings, a vial with a blue band near its base, and two different colored needle attachments (one white, one blue) positioned beside the syringe and vial. The illustration likely depicts items used for medication preparation or administration.*

FDA Label Image

Image (Zynrelef 121)

ZYNRELEF 200 mg/7mL prefilled syringe packaging label from Heron Therapeutics, Inc. The label shows the proprietary name ZYNRELEF prominently with the strength 200 mg/7mL, indicating a liquid injectable dosage form. The label includes regulatory and product identification markings typical for pharmaceutical packaging.*

FDA Label Image

Image (Zynrelef 122)

An instructional illustration showing the proper removal of the shroud from the base of a device, using hands to grip and pull the parts apart. The image highlights the components labeled 'Shroud' and 'Base' with arrows indicating the direction of movement.*

FDA Label Image

Image (Zynrelef 123)

An instructional illustration showing a hand gripping a small vial or container with a blue band, and an arrow pointing downward above it, indicating a pressing or pushing action. The container is placed on a flat base or holder.*

FDA Label Image

Image (Zynrelef 124)

ZYNRELEF 200 and 400 mg/7mL and mg/14mL injectable solution carton. The packaging is predominantly white with blue and green highlights and features the Heron Therapeutics, Inc. logo. The label displays the proprietary name, strength, and volume of the product.*

FDA Label Image

Image (Zynrelef 125)

ZYNRELEF 200; 6 mg/7mL and 400; 12 mg/14mL injection bottles by Heron Therapeutics, Inc. The image shows two clear glass vials with white caps, labeled with the proprietary name, strength, and volume of the injectable solution.*

FDA Label Image

Image (Zynrelef 126)

An instructional illustration showing hands snapping the top off a vial or cartridge, possibly related to the preparation or use of ZYNRELEF. The image highlights the action with the word 'SNAP' and a downward arrow, indicating how to open the container.*

FDA Label Image

Image (Zynrelef 127)

FDA Label Image

Image (Zynrelef 128)

An instructional illustration demonstrating the correct technique to draw medication from a vial into a syringe. It shows hands holding the vial and syringe, with arrows indicating the rotational motion needed while pulling the syringe plunger.*

FDA Label Image

Image (Zynrelef 129)

Illustration showing a hand holding a syringe attached to a vial, with an inset detail highlighting the drug inlet on the vial. The syringe is marked with measurement units for liquid volume.*

FDA Label Image

Image (Zynrelef 130)

An instructional illustration showing a gloved hand using a syringe to draw liquid from a vial. The syringe is marked with measurement graduations, and the vial has a blue cap. This image likely depicts the preparation steps for administering a medication.*

FDA Label Image

Image (Zynrelef 131)

Illustration showing a hand holding a ZYNRELEF 200 mg/7 mL vial with an attached syringe. The syringe is drawn from the vial, with a close-up inset of the filled syringe, demonstrating proper withdrawal technique for this Heron Therapeutics, Inc. product.*

FDA Label Image

Image (Zynrelef 132)

FDA Label Image

Image (Zynrelef 133)

An instructional illustration showing a syringe injecting medication into a layered skin section, depicting subcutaneous or local tissue administration. The needle is inserted into a diagonal incision or space within the skin layers, indicating method of drug delivery for ZYNRELEF.*

FDA Label Image

Image (Zynrelef 134)

FDA Label Image

Image (Zynrelef 135)

FDA Label Image

Image (Zynrelef 136)

ZYNRELEF 200, 6 mg/7 mL injection vial packaging label. The label includes the proprietary name ZYNRELEF, the active ingredient strengths of 6 mg per 7 mL and 12 mg per 14 mL, and the labeler Heron Therapeutics, Inc. The vial is clear and displays dosage volume markings.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for ZYNRELEF 400 mg bupivacaine and 12 mg meloxicam extended-release solution. The label indicates single-dose application for instillation use, with each mL containing 29.25 mg bupivacaine and 0.88 mg meloxicam. The package includes one 14 mL vial and various application components. Labeler is Heron Therapeutics, Inc.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for ZYNRELEF extended-release solution, containing 300 mg bupivacaine and 9 mg meloxicam per vial. The single-dose vial has 10.5 mL total volume for instillation use. Label shows bupivacaine and meloxicam strengths, instructions for use, storage conditions, and contents including syringes. Manufactured by Heron Therapeutics, Inc.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for ZYNRELEF 200 mg bupivacaine and 6 mg meloxicam extended-release solution for single-dose instillation use. The label indicates 7 mL vial contents with detailed instructions and storage conditions. Heron Therapeutics, Inc. is the labeler. The label includes lot number, expiration date, and barcode.*

FDA Label Image

Principal Display Panel (Kit Carton)

ZYNRELEF 60 mg bupivacaine and 1.8 mg meloxicam extended-release solution carton for single-dose application for instillation use. The label indicates the vial contains 2.3 mL with detailed instructions and storage conditions from Heron Therapeutics, Inc. The packaging includes product branding and dosage information, highlighting its contents and usage components.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for ZYNRELEF extended-release solution containing 400 mg bupivacaine and 12 mg meloxicam per 14 mL vial. The label indicates single-dose application for instillation use, with instructions and storage conditions. Labeler is Heron Therapeutics, Inc. The label includes barcode and product NDC 47426-501-02.*

FDA Label Image

Principal Display Panel (Kit Carton)

Box label for ZYNRELEF extended-release solution containing 300 mg bupivacaine and 9 mg meloxicam per vial. The label indicates a single-dose application for instillation use, with 10.5 mL vial contents. Manufacturer is Heron Therapeutics, Inc. The label includes storage instructions, kit contents, and dosage information.*

FDA Label Image

Principal Display Panel (Kit Carton)

ZYNRELEF 200 mg bupivacaine and 6 mg meloxicam extended-release solution packaging label for a single-dose application vial containing 7 mL. The label indicates it is for instillation use, with details on contents, storage, and kit components. Manufactured by Heron Therapeutics, Inc., the label includes NDC 47426-503-01 and emphasizes use of supplied components only.*

FDA Label Image

Principal Display Panel (Kit Carton)

The packaging label for ZYNRELEF extended-release solution features the active ingredients bupivacaine and meloxicam at strengths of 60 mg and 1.8 mg respectively. The label indicates a single-dose application for instillation use. It provides dosage details per mL and includes instructions to refer to prescribing information. The label also notes vial contents of 2.3 mL and manufacturer Heron Therapeutics, Inc. The NDC 47426-504-01 is visible along with storage instructions and kit contents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.